Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in myonuclei | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 13856
Sealed predictions
- FTCDNL1 in dopamine neurons, braak-0.67 (p 0.049) → -0.47 (p 0.206)receipt 13864
- FTCDNL1 in oligodendrocytes, braak-0.21 (p 0.584) → -0.10 (p 0.807)receipt 13863
Swarm cases
receipt 13864: FTCDNL1 in dopamine neurons, braak
- power
- full sample -0.50 (p 0.034, n 18), 95% CI -0.78 to -0.04. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.50 (p 0.034, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.50 (p 0.034, n 18). not the mix.
- skeptic
- leave-one-out range -0.59 to -0.42, sign flips 0; without severely affected donors -0.50 (p 0.034, n 18). robust.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FTCDNL1 in dopamine neurons.
case closed: nothing better to follow up.
receipt 13863: FTCDNL1 in oligodendrocytes, braak
- power
- full sample -0.02 (p 0.935, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.05 (p 0.834, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.08 (p 0.748, n 18). could be the mix.
- skeptic
- leave-one-out range -0.13 to +0.13, sign flips 5; without severely affected donors -0.02 (p 0.935, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FTCDNL1 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts